Download | < Back |
13 Dec 2021 | |
Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Cryopyrin-Associated Periodic Syndrome (CAPS) in Australia | |
View all announcements for CADILA HEALTHCARE LTD. | Source: BSE India |